505(b)(2) Standards Needed To Ensure Predictability – Pfizer Attorney
Executive Summary
FDA should develop standards for use of the 505(b)(2) approval pathway to better allow for predictability of its application, according to Pfizer Assistant General Council Jeffrey Chasnow
You may also be interested in...
Abraxane sNDA Is 505(b)(2) Test, But Panel Has Efficacy, Labeling Questions
One obstacle to using the 505(b)(2) pathway for approving efficacy supplements appears to be how to characterize an agent's effectiveness in labeling
Abraxane sNDA Is 505(b)(2) Test, But Panel Has Efficacy, Labeling Questions
One obstacle to using the 505(b)(2) pathway for approving efficacy supplements appears to be how to characterize an agent's effectiveness in labeling
Pfizer’s Omnitrope Options Include Approval Challenge, Substitutability Fight
Pfizer's response to the approval of Sandoz' Omnitrope could signal the extent to which industry gauges the legality of approving follow-on biologics under the 505(b)(2) pathway